Arrhythmia Disorders News

A healthy sleep pattern, as well as improving sleep habits, were associated with a lower risk for atrial fibrillation recurrence in patients who underwent catheter ablation for AF, researchers reported.

An analysis of more 800 MRI examinations shows the scans do not induce clinically significant functional changes in non-MRI-conditional implantable cardioverter defibrillators, data from a single-center study show.

Atrial fibrillation was associated with mortality in patients with significant aortic stenosis, but correction for left ventricular diastolic function rendered the association not significant, researchers reported.

Despite atrial fibrillation ablation conferring greater quality of life benefits vs. drug therapy in the CABANA trial, sex-based differences in quality of life persisted, according to a new analysis from the trial.

A delay in time to catheter ablation after an atrial fibrillation diagnosis is associated with increased mortality risk as well as trends of increased risk for HF hospitalization and AF recurrence, researchers reported.

The FDA granted fast track designation for Tecarfarin, a novel cardiorenal therapy by Cadrenal Therapeutics, to prevent systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation.

An IV bolus of adenosine administered 10 minutes after radiofrequency ablation of the accessory pathway has the same diagnostic accuracy as waiting 30 minutes for predicting the resumption of pathway conduction, researchers reported.

A novel catheter for very high-power short-duration ablation for pulmonary vein isolation in patients with atrial fibrillation modestly reduced procedure time compared with standard ablation, according to data from the POWER PLUS trial.

In patients with atrial fibrillation, participating in an exercise-based intervention for 6 months reduced AF recurrence and improved symptom severity compared with controls, researchers reported.

Efficacy and safety of self-administered nasal spray (etripamil, Milestone Pharmaceuticals) in patients who experience paroxysmal ventricular tachycardia in an at-home setting.